靶向药物赫赛汀、化疗联合治疗晚期乳腺癌的临床疗效及对患者炎症因子水平的影响

Clinical efficacy of targeted drug Herceptin combined with chemotherapy in the treatment of advanced breast cancer and its influence on inflammatory factor levels in patients

目的 研究靶向药物曲妥珠单抗 ( 商品名 :赫赛汀 )、化疗联合治疗晚期乳腺癌的临床疗效及对患者炎症因子水平的影响。方法 120 例晚期乳腺癌患者 , 按照 Excel 函数法分为对照组与实验组 , 每组 60 例。对照组给予化疗治疗 , 实验组给予赫赛汀联合化疗治疗。比较两组患者治疗前后血清炎症因子[白细胞介素 (IL)-2、IL-6、IL-10、肿瘤坏死因子 -α(TNF-α)、 C- 反应蛋白 (CRP)]、T 淋巴细胞[CD3^(+)、CD4^(+)、CD8^(+)、CD4^(+)/CD8^(+)]水平以及治疗效果。结果 治疗后 , 两组患者 IL-2、IL-6、IL-10、TNF-α、CRP 水平较治疗前均改善 , 且实验组改善幅度大于对照组 , 差异均具有统计学意义(P<0.05)。治疗后 , 实验组患者 CD3^(+)(63.19±4.75)%、CD4^(+)(39.82±2.81)%、CD8^(+)(25.32±2.79)%、CD4^(+)/CD8^(+)(1.39±0.25) 均优于对照组的 (54.18±4.12)%、(32.16±2.91)%、(28.39±2.63)%、(1.12±0.29), 差异均具有统计学意义 (P<0.05)。实验组治疗总有效率 96.67% 高于对照组的 85.00%, 差异具有统计学意义(P<0.05)。结论 靶向药物赫赛汀、化疗联合治疗晚期乳腺癌的临床疗效显著提升 , 且对患者炎症因子水平改善较为显著。值得临床推广。

Objective To study the clinical efficacy of targeted drug trastuzumab(trade name:Herceptin)combined with chemotherapy in the treatment of advanced breast cancer and its influence on inflammatory factor levels in patients.Methods A total of 120 patients with advanced breast cancer were divided into control group and experimental group according to the Excel function method,with 60 cases in each group.The control group was treated with chemotherapy,while the experimental group was treated with Herceptin combined with chemotherapy.Comparison was made on serum inflammatory factors[interleukin(IL)-2,IL-6,IL-10,tumor necrosis factor-α(TNF-α),C-reactive protein(CRP)],T lymphocytes[CD3^(+),CD4^(+),CD8^(+),CD4^(+)/CD8^(+)]levels before and after treatment,and therapeutic effects between the two groups.Results After treatment,the levels of IL-2,IL-6,IL-10,TNF-α,and CRP in the two groups were improved compared with those before treatment in this group,and the improvement in the experimental group was greater than that in the control group,and the differences were all statistically significant(P<0.05).After treatment,the CD3^(+)(63.19±4.75)%,CD4^(+)(39.82±2.81)%,CD8^(+)(25.32±2.79)%,CD4^(+)/CD8^(+)(1.39±0.25)%in the experimental group were better than(54.18±4.12)%,(32.16±2.91)%,(28.39±2.63)%,(1.12±0.29)in the control group,and the differences were all statistically significant(P<0.05).The total effective rate 96.67%of the experimental group was higher than 85.00%of the control group,and the difference was statistically significant(P<0.05).Conclusion Targeted drug Herceptin in combination with chemotherapy has significant clinical efficacy on patients with advanced breast cancer,and can significantly improve the inflammatory factor level,which is worthy of clinical promotion.